S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

NASDAQ:SLGL - Sol Gel Technologies Stock Price, Forecast & News

$11.21
-0.73 (-6.11 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$11.04
Now: $11.21
$11.77
50-Day Range
$10.60
MA: $12.86
$15.46
52-Week Range
$6.11
Now: $11.21
$21.00
Volume163,963 shs
Average Volume107,630 shs
Market Capitalization$228.57 million
P/E RatioN/A
Dividend YieldN/A
Beta1.28
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLGL
CUSIPN/A
Phone972-8931-3429

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$130,000.00
Book Value$3.38 per share

Profitability

Net Income$-32,200,000.00
Net Margins-223.99%

Miscellaneous

EmployeesN/A
Market Cap$228.57 million
Next Earnings Date3/19/2020 (Estimated)
OptionableNot Optionable

Receive SLGL News and Ratings via Email

Sign-up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.


Sol Gel Technologies (NASDAQ:SLGL) Frequently Asked Questions

What is Sol Gel Technologies' stock symbol?

Sol Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL."

How were Sol Gel Technologies' earnings last quarter?

Sol Gel Technologies Ltd (NASDAQ:SLGL) announced its earnings results on Wednesday, November, 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.12. The firm had revenue of $4.73 million for the quarter, compared to analyst estimates of $6.56 million. Sol Gel Technologies had a negative return on equity of 71.98% and a negative net margin of 223.99%. View Sol Gel Technologies' Earnings History.

When is Sol Gel Technologies' next earnings date?

Sol Gel Technologies is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for Sol Gel Technologies.

What price target have analysts set for SLGL?

4 brokers have issued twelve-month target prices for Sol Gel Technologies' shares. Their forecasts range from $23.00 to $33.00. On average, they expect Sol Gel Technologies' share price to reach $26.50 in the next twelve months. This suggests a possible upside of 136.4% from the stock's current price. View Analyst Price Targets for Sol Gel Technologies.

What is the consensus analysts' recommendation for Sol Gel Technologies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sol Gel Technologies in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sol Gel Technologies.

Has Sol Gel Technologies been receiving favorable news coverage?

Media headlines about SLGL stock have been trending very negative this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sol Gel Technologies earned a news impact score of -3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Sol Gel Technologies.

Are investors shorting Sol Gel Technologies?

Sol Gel Technologies saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 68,600 shares, an increase of 27.5% from the January 15th total of 53,800 shares. Based on an average daily volume of 89,000 shares, the short-interest ratio is currently 0.8 days. Currently, 1.8% of the shares of the company are sold short. View Sol Gel Technologies' Current Options Chain.

Who are some of Sol Gel Technologies' key competitors?

What other stocks do shareholders of Sol Gel Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sol Gel Technologies investors own include NVIDIA (NVDA), Tesla (TSLA), CareDx (CDNA), Iovance Biotherapeutics (IOVA), Micron Technology (MU), Netflix (NFLX), Novavax (NVAX), Tandem Diabetes Care (TNDM), Alibaba Group (BABA) and Verizon Communications (VZ).

Who are Sol Gel Technologies' key executives?

Sol Gel Technologies' management team includes the folowing people:
  • Dr. Alon Seri-Levy, Co-Founder, CEO & Director (Age 58)
  • Mr. Gilad Mamlok, Chief Financial Officer (Age 51)
  • Mr. Itzik Yosef, VP of Operations (Age 43)
  • Dr. Ofer Toledano, VP of R&D (Age 54)
  • Dr. Ofra Levy-Hacham Ph.D., VP of Clinical & Regulatory Affairs (Age 53)

When did Sol Gel Technologies IPO?

(SLGL) raised $60 million in an initial public offering (IPO) on Thursday, February 1st 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. ​Jefferies and BMO Capital Markets​ served as the underwriters for the IPO and JMP Securities and Raymond James​ were co-managers.

Who are Sol Gel Technologies' major shareholders?

Sol Gel Technologies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Phoenix Holdings Ltd. (10.35%), Broadfin Capital LLC (2.56%), Raymond James & Associates (0.17%), Raymond James Financial Services Advisors Inc. (0.16%), Renaissance Technologies LLC (0.07%) and Tower Research Capital LLC TRC (0.02%).

Which institutional investors are selling Sol Gel Technologies stock?

SLGL stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Renaissance Technologies LLC, Raymond James & Associates and Raymond James Financial Services Advisors Inc..

Which institutional investors are buying Sol Gel Technologies stock?

SLGL stock was bought by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd. and Tower Research Capital LLC TRC .

How do I buy shares of Sol Gel Technologies?

Shares of SLGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sol Gel Technologies' stock price today?

One share of SLGL stock can currently be purchased for approximately $11.21.

How big of a company is Sol Gel Technologies?

Sol Gel Technologies has a market capitalization of $228.57 million and generates $130,000.00 in revenue each year. The company earns $-32,200,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. View Additional Information About Sol Gel Technologies.

What is Sol Gel Technologies' official website?

The official website for Sol Gel Technologies is http://www.sol-gel.com/.

How can I contact Sol Gel Technologies?

Sol Gel Technologies' mailing address is 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403650. The company can be reached via phone at 972-8931-3429 or via email at [email protected]


MarketBeat Community Rating for Sol Gel Technologies (NASDAQ SLGL)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Sol Gel Technologies and other stocks. Vote "Outperform" if you believe SLGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel